Ethics Survey: Drug testing remains a clinical tug of war

May 18, 2017 Julie Miller

Julie Miller, Editor in Chief

Treatment centers must weigh costs and clinical needs when creating policies for patient drug testing. Meanwhile, investors are examining how drug testing fits in the greater scheme of profits and regulatory risks.

Previous Article
TCEM: Proving value will be the challenge for the future

BHE StaffAt the Treatment Center Executive and Marketing Retreat, CEO Doug Tieman recommended that today’s ...

Next Article
NAPHS names director of policy and regulatory affairs

Tom Valentino, Senior EditorScott Dziengelski, former law director for U.S. Rep. Tim Murphy of Pennsylvania...

×

Have Behavioral Health Business updates sent to your inbox today!

First Name
Last Name
Thank you!
Error - something went wrong!